<DOC>
	<DOCNO>NCT01840501</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics ( body medication ) , potential immunogenicity ( ability induce immune response ) , pharmacodynamics ( drug body ) administration JNJ-42721458 healthy adult male participant .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Pharmacokinetics Pharmacodynamics JNJ-42721458 Healthy Male Participants</brief_title>
	<detailed_description>This randomize ( study medication assign chance ) , double-blind ( neither physician participant know identity assign treatment ) , placebo-controlled ( inactive substance compare medication test whether medication real effect clinical study ) , single-ascending ( increase ) dose multiple-ascending dose study JNJ-42721458 compound healthy male . The study divide two part . Part 1 single-ascending dose ( SAD ) study include 10 panel ( use ascend dos start 0.1 mg ) single dose study medication administer Day 1 . Part 2 multiple-ascending dose ( MAD ) study include approximately 6 panel ( use ascend dos start 5.0 mg ) multiple dos study medication administer daily 10 day . Part 2 initiated completion dose relevant evaluation Part 1 . In panel Part 1 2 , 6 participant randomly assign receive JNJ-42721458 2 participant randomly assign placebo . Safety evaluation include assessment adverse event , physical examination , laboratory test , vital sign , electrocardiogram , cardiac telemetry evaluation injection sit monitor throughout study . The total study duration participant approximately 6-7 week Part 1 7-8 week participant Part 2 .</detailed_description>
	<criteria>Body mass index ( weight kg/m2 ) 18 30 kg/m2 , body weight less 50 kg Participant judge generally good health base medical history , physical examination , vital sign laboratory safety test Blood pressure 90 135 mmHg systolic , inclusive , high 90 mmHg diastolic A 12lead electrocardiogram consistent normal cardiac conduction function History current clinically significant medical illness Clinically significant abnormal value hematology , clinical chemistry urinalysis screen Day 1 ( admission study center ) Estimated creatinine clearance less equal 80 mL/min Clinically significant abnormal physical examination , vital sign 12 lead electrocardiogram screen Day 1 Participant demonstrate orthostatic change vital sign measurement screen predose go semi recumbent stand position History significant multiple and/or severe allergy ( include latex allergy ) know history clinically significant allergy polyethylene glycol ( PEG ) contain PEGylated product</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Healthy</keyword>
	<keyword>JNJ-42721458</keyword>
	<keyword>Male</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>